InTest (INTT) Q1 2026 earnings review
Diversification Strategy Pays Off as Revenue Surges
InTest's aggressive push to diversify beyond the cyclical semiconductor market is working. First-quarter revenue jumped 27% YoY to $33.9 million, driven by massive gains in Defense/Aerospace and Life Sciences. The company capitalized on a heavy backlog, driving gross margins up 400 basis points YoY to 45.5% and returning the business to solid profitability after a bruising early 2025. While total orders decelerated sequentially, management is confident enough in the broader macro recovery to raise full-year revenue guidance. The turnaround is real, but an ongoing slump in new semiconductor orders remains a stubborn anchor.
🐂 Bull Case
Non-semiconductor markets now account for 69% of total revenue. Defense/Aerospace revenue grew 106% YoY, and Life Sciences grew 112% YoY, proving the company can thrive even when its legacy chip business struggles.
Gross margin expanded to 45.5% (up 400 bps YoY). Management successfully leveraged higher manufacturing volumes and a favorable product mix to drive profitability, laying the groundwork for stronger free cash flow.
🐻 Bear Case
Despite management claiming the 'Semi business improved,' the data shows Semi orders collapsed 20.4% YoY and 18.7% sequentially. The current Semi revenue bump is purely backlog conversion, not fresh demand.
Total orders fell 15.2% from 25Q4 to $31.8 million in 26Q1. InTest burned through $2.1 million of its backlog this quarter. If order momentum doesn't recover, revenue growth will eventually stall.
⚖️ Verdict: 🟢
Bullish. The strategic pivot away from semiconductor over-reliance is bearing fruit faster than expected. Margin expansion and raised full-year guidance show a management team in control of its operational levers.
Key Themes
Defense and Life Sciences Drive the Top Line
The company's revenue growth is heavily concentrated in its newest verticals. Defense/Aerospace revenue hit $5.8 million (+106% YoY), and Life Sciences reached $3.6 million (+112% YoY). This confirms that new product engineering and sales integration from recent M&A are translating directly into billed revenue.
Backlog Conversion Fuels Revenue
InTest ended Q1 with a $51.8 million backlog, up 35.5% YoY. Approximately 50% of this backlog is expected to ship beyond Q2 2026. This massive buffer is allowing the company to post strong revenue numbers and maintain high factory utilization even as current-quarter orders normalize.
Cross-Business Product Synergies
CEO Rich Rogoff explicitly prioritized removing 'operational friction' to accelerate cross-business product development. By combining thermal, mechanical, and electronic testing capabilities across its portfolio companies, InTest is actively increasing its total addressable market per customer, a key lever for future organic growth.
Semiconductor Narrative Contradicts the Data
Management stated in the PR that the 'Semi business improved.' While true for revenue (+16.8% YoY), this masks a deeper problem: Semiconductor orders plummeted 20.4% YoY to just $7.7 million. The segment's book-to-bill ratio was an anemic 0.73 in Q1. The chip cycle has not yet bottomed for InTest.
Macro Environment Still Pressuring CapEx
While the company raised guidance based on 'improving market conditions,' sequential orders declined 15.2% overall. Safety/Security orders fell 61.5% YoY, and Industrial orders fell 9.4% YoY. This indicates that while InTest's niche M&A targets are outperforming, broader industrial capital expenditure hesitancy remains a headwind.
Restricted Cash Tied to Debt Covenants
The company entered a covenant waiver agreement with its U.S. lender in August 2025, lasting through Q1 2026. This forces InTest to pledge cash equal to its outstanding U.S. debt ($2.8 million as of March 31). While the debt load is small, this restricts capital deployment flexibility for targeted M&A or organic investments until the waiver expires.
Other KPIs
Reversing. Despite posting a net profit, InTest used $3.3 million in operating cash this quarter, a sharp negative swing compared to generating $5.5 million in 25Q1. This was primarily driven by a $3.8 million increase in Trade Accounts Receivable and a $2.3 million decrease in Accounts Payable, indicating working capital buildup required to fund the current revenue surge.
Accelerating dramatically compared to negative 3.3% in the prior year period. Management stripped out $0.7 million in CEO transition restructuring costs to highlight the underlying operational leverage. If they can hold gross margins at 45.5%, EBITDA margins should sustainably clear 10% in the back half of the year.
Guidance
Accelerating. The midpoint of $132.5 million represents a raise from prior expectations and implies roughly 16% YoY growth compared to the depressed $113.8 million printed in FY25. This shows high confidence in backlog conversion and non-semi demand.
Decelerating sequentially. The $33 million midpoint is slightly lower than the $33.9 million achieved in Q1, but still represents a robust 17% YoY growth rate over 25Q2 ($28.1M). This conservative pacing accounts for the lower order intake observed in Q1.
Stable. Management expects the 45.5% achieved in Q1 to be the run-rate for the year. This requires flawless supply-chain execution and product mix management, especially if high-margin semiconductor revenue continues to lag.
Key Questions
Semiconductor Order Visibility
With Semi orders falling 20% YoY to $7.7 million, what specific leading indicators or customer conversations give you confidence in the 'early signs of improvement in our back-end Semi funnel' mentioned in the press release?
Working Capital and Cash Flow
Operating cash flow turned negative this quarter due to a buildup in receivables. Do you expect this working capital dynamic to reverse in Q2, and what is your target for full-year free cash flow conversion?
M&A Strategy and Covenant Constraints
You highlighted targeted M&A as a capital deployment priority, yet cash is currently restricted under a debt covenant waiver. Does the amendment extending through August 2026 limit your ability to execute on acquisitions in the near term?